Alvotech (NASDAQ:ALVO – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Alvotech to similar businesses based on the strength of its earnings, dividends, institutional ownership, valuation, profitability, risk and analyst recommendations.
Profitability
This table compares Alvotech and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alvotech | -50.62% | N/A | -11.71% |
| Alvotech Competitors | -12,516.26% | -215.91% | -31.70% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Alvotech and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alvotech | 2 | 0 | 5 | 0 | 2.43 |
| Alvotech Competitors | 9920 | 15331 | 45734 | 1601 | 2.54 |
Volatility & Risk
Alvotech has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, Alvotech’s rivals have a beta of -1.85, suggesting that their average stock price is 285% less volatile than the S&P 500.
Insider and Institutional Ownership
47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 0.5% of Alvotech shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Alvotech and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Alvotech | $489.61 million | $27.92 million | -5.55 |
| Alvotech Competitors | $750.45 million | $11.26 million | -18.51 |
Alvotech’s rivals have higher revenue, but lower earnings than Alvotech. Alvotech is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
Alvotech beats its rivals on 7 of the 13 factors compared.
About Alvotech
Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.
Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.
